Spexis announces the publication of promising results for a novel class of macrocyclic,…
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of preclinical results from the company’s…